Psilocybin

Psilocybe mushrooms, psilocybin & psilocin


 

See all (314)


All Research

Isbell (1959). Comparison of the reactions induced by psilocybin and LSD-25 in man. Psychopharmacologia.

Meldrum & Naquet (1971). Effects of psilocybin, dimethyltryptamine, mescaline and various lysergic acid derivatives on the EEG and on photically induced epilepsy in the baboon (Papio papio). Electroencephalography & Clinical Neurophysiology.

Kolarĩk (1971). EEG changes after psilocybin in organic brain lesions. Activitas Nervosa Superior.

Borowiak, Ciechanowksi & Waloszcyk (1998). Psilocybin mushroom (Psilocybe semilanceata) intoxication with myocardial infarction. Journal of Toxicology.

Schechter & Rosecrans (1972). Lysergic acid diethylamide (LSD) as a discriminative cue: Drugs with similar stimulus properties. Psychopharmacologia.

Hill & Fischer (1973). Induction and extinction of psilocybin induced transformations of visual space. Pharmakopsychiatrie, Neuro-Psychopharmakologie.

Tilson, Marquis & Rech (1973). The effects of d-amphetamine, 2,5-dimethoxy-4-methyl-amphetamine (DOM), and psilocybin on fixed-interval responding in the rat. Proceedings of the Annual Convention of the American Psychological Association.

Aboul-Enein (1974). Psilocybin: a pharmacological profile. American Journal of Pharmacy and the Sciences of Supporting Public Health.

Fanciullacci, Franchi & Sicuteri (1974). Hypersensitivity to lysergic acid diethylamide (LSD-25) and psilocybin in essential headache. Experientia.

Horibe (1974). The effects of psilocybin on EEG and behavior in monkeys. Activitas Nervosa Superior.

Ladefoged (1974). The effect of LSD, psilocybin, harmaline and amphetamine on the body temperature of para-chlorophenylalanine pretreated rabbits. Archives Internationales de Pharmacodynamie et de Therapie.

Greenberg, Kuhn & Appel (1975). Comparison of the discriminative stimulus properties of D9-THC and psilocybin in rats. Pharmacology, Biochemistry and Behavior.

Pollock (1975). The psilocybin mushroom pandemic. Journal of Psychedelic Drugs.

Guzmán & Ott (1976). Description and chemical analysis of a new species of hallucinogenic Psilocybe from the Pacific Northwest. Mycologia.

Ott & Guzman (1976). Detection of psilocybin in species of Psilocybe, Panaeolus and Psathyrella. Lloydia.

Parashos (1976). The psilocybin-induced "state of drunkenness" in normal volunteers and schizophrenics. Behavioral Neuropsychiatry.

Pollock (1976). Liberty caps: recreational hallucinogenic mushrooms. Drug and Alcohol Dependence.

Davis & Walters (1977). Psilocybin: biphasic dose-response effects on the acoustic startle reflex in the rat. Pharmacology, Biochemistry, and Behavior.

Martindale & Fischer (1977). The effects of psilocybin on primary process content in language. Confinia Psychiatrica.

Repke & Leslie (1977). Baeocystin in Psilocybe semilanceata. Journal of Pharmaceutical Sciences.

Repke, Leslie & Guzmán (1977). Baeocystin in psilocybe, conocybe and panaeolus. Lloydia.

Repke et al. (1977). GLC-mass spectral analysis of psilocin and psilocybin. Journal of Pharmaceutical Sciences.

Rhead (1977). The use of psychedelic drugs in the treatment of severely disturbed children: A review. Journal of Psychedelic Drugs.

Castellano (1978). Effects of mescaline and psilocin on acquisition, consolidation, and performance of light-dark discrimination in two inbred strains of mice. Psychopharmacology.

Hatfield & Valdes (1978). The occurrence of psilocybin in Gymnopilus species. Lloydia.

Hyde et al. (1978). Abuse of indigenous psilocybin mushrooms: A new fashion and some psychiatric complications. The British Journal of Psychiatry.

Pollock (1978). Psychotropic mushrooms and the alteration of consciousness: I. The ascent of psilocybian mushroom consciousness. Journal of Altered States of Consciousness.

Van Went (1978). Mutagenicity testing of 3 hallucinogens: LSD, psilocybin and delta 9-THC, using the micronucleus test. Experientia.

Benjamin (1979). Persistent psychiatric symptoms after eating psilocybin mushrooms. British Medical Journal.

Chilton, Bigwood & Jensen (1979). Psilocin, bufotenine and serotonin: historical and biosynthetic observations. Journal of Psychedelic Drugs.

Guest & Consroe (1979). Psilocybin neuropsychopharmacology in rabbits. Research Communications in Psychology, Psychiatry & Behavior.

Mills, Lesinskas & Watkinson (1979). The danger of hallucinogenic mushrooms. Scottish Medical Journal.

Dewhurst (1980). Psilocybin intoxication. The British Journal of Psychiatry.

McDonald (1980). Mushrooms and madness. Hallucinogenic mushrooms and some psychopharmacological implications. Canadian Journal of Psychiatry.

Shulgin (1980). Psilocybin. Journal of Psychedelic Drugs.

Thomson (1980). Analysis of psilocybin and psilocin in mushroom extracts by reversed-phase high performance liquid chromatography. Journal of Forensic Sciences.

Beug & Bigwood (1981). Quantitative analysis of psilocybin and psilocin in psilocybe baeocystis (Singer and Smith) by high-performance liquid chromatography and by thin-layer chromatography. Journal of Chromatography.

Christiansen, Rasmussen & Hoiland (1981). The content of psilocybin in Norwegian Psilocybe semilanceata. Planta Medica.

DiPalma (1981). Mushroom poisoning. American Family Physician.

Gelpke (1981). On travels in the universe of the soul: reports on self-experiments with delysid (LSD) and psilocybin (CY). Journal of Psychoactive Drugs.

Migliaccio et al. (1981). Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy. Journal of Medicinal Chemistry.

Stienstra et al. (1981). [Psilocybine poisoning resulting from eating mushrooms]. Nederlands Tijdschrift Voor Geneeskunde.

Beug & Bigwood (1982). Psilocybin and psilocin levels in twenty species from seven genera of wild mushrooms in the Pacific Northwest, U.S.A. Journal of Ethnopharmacology.

Bigwood & Beug (1982). Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (Earle) Singer. Journal of Ethnopharmacology.

Halaris (1982). Nerve terminal effects of indoleamine psychotomimetics on 5-hydroxytryptamine. Neuroscience and Biobehavioral Reviews.

Koerner & Appel (1982). Psilocybin as a discriminative stimulus: Lack of specificity in an animal behavior model for "hallucinogens." Psychopharmacology.

Peden & Pringle (1982). Hallucinogenic fungi. The Lancet.

Peden, Pringle & Crooks (1982). The problem of psilocybin mushroom abuse. Human & Experimental Toxicology.

van Poorten et al. (1982). Physostigmine reversal of psilocybin intoxication. Anesthesiology.

Mack (1983). Phenomenally phunny phungi--psilocybin toxicity. North Carolina Medical Journal.

McGuire (1982). Ancient Maya mushroom connections: a transcendental interaction model. Journal of Psychoactive Drugs.

Sottolano & Lurie (1983). The quantitation of psilocybin in hallucinogenic mushrooms using high performance liquid chromatography. Journal of Forensic Sciences.

Badham (1984). Ethnobotany of psilocybin mushrooms, especially Psilocybe cubensis. Journal of ethnopharmacology.

Christiansen, Ramussen & Hoiland (1984). Detection of psilocybin and psilocin in Norwegian species of Pluteus and Conocybe. Planta Medica.

Høiland et al. (1984). [New hallucinogenic mushrooms in Norway]. Tidsskrift for den Norske Laegeforening.

Jokiranta et al. (1984). Psilocybin in Finnish Psilocybe semilanceata. Planta Medica.

Vanhaelen-Fastré & Vanhaelen (1984). Qualitative and quantitative determinations of hallucinogenic components of psilocybe mushrooms by reversed-phase high-performance liquid chromatography. Journal of Chromatography.

Casale (1985). An aqueous-organic extraction method for the isolation and identification of psilocin from hallucinogenic mushrooms. Journal of Forensic Sciences.

Kysilka et al. (1985). High-performance liquid chromatographic determination of hallucinogenic indoleamines with simultaneous UV photometric and voltammetric detection. Journal of Chromatography.

Lee (1985). A technique for the rapid isolation and identification of psilocin from psilocin/psilocybin-containing mushrooms. Journal of Forensic Science.

Stijve, Klan & Kuyper (1985). Occurrence of psilocybin and baeocystin in the genus Inocybe. Persoonia.

Thompson et al. (1985). Mushroom use by college students. Journal of Drug Education.

Stijve & Kuyper (1986). Occurrence of psilocybin in various higher fungi from several european countries. Nestle Research News.

Gartz (1987). Occurrence of psilocybin and baeocystin in fruit bodies of Pluteus salicinus.

Ohenoja et al. (1987). The occurrence of psilocybin and psilocin in Finnish fungi. Journal of Natural Products.

Musha et al. (1988). [Poisoning by the hallucinogenic mushroom hikageshibiretake (Psilocybe argentipes)--with special reference to subjective experiences during psilocybin poisoning]. Seishin Shinkeigaku Zasshi.

Schwartz & Smith (1988). Hallucinogenic mushrooms. Clinical Pediatrics.

Eivindvik, Rasmussen & Sund (1989). Handling of psilocybin and psilocin by everted sacs of rat jejunum and colon. Acta Pharmaceutica Nordica.

Gartz (1989). Occurrence of psilocybin, psilocin and baeocystin in Gymnopilus purpuratus. Persoonia.

Gartz (1989). Biotransformation of tryptamine in fruiting mycelia of Psilocybe cubensis. Planta Medica.

Gartz (1989). Biotransformation of tryptamine derivatives in mycelial cultures of Psilocybe. Journal of Basic Microbiology.

Kysilka & Wurst (1989). High-performance liquid chromatographic determination of some psychotropic indole derivatives. Journal of Chromatography.

Kysilka (1990). Determination of psilocin in rat urine by high-performance liquid chromatography with electrochemical detection. Journal of Chromatography.

Kysilka & Wurst (1990). A novel extraction procedure for psilocybin and psilocin determination in mushroom samples. Planta Medica.

Lassen, Ravn & Lassen (1990). [Hallucinogenic psilocybine containing mushrooms. Toxins contained in Danish wild mushrooms]. Ugeskrift for Laeger.

Allen & Merlin (1992). Psychoactive mushroom use in Koh Samui and Koh Pha-Ngan, Thailand. Journal of Ethnopharmacology.

Lassen, Lassen & Skov (1992). [Consumption of psilocybin-containing hallucinogenic mushrooms by young people]. Ugeskrift for Laeger.

Raff, Halloran & Kjellstrand (1992). Renal failure after eating "magic" mushrooms. CMAJ.

Gable (1993). Skinner, Maslow, and psilocybin. Journal of Humanistic Psychology.

Lassen, Lassen & Skov (1993). [Hallucinogenic psilocybine-containing mushrooms. Patterns of use among Danish abusers]. Ugeskrift for Laeger.

Merlin & Allen (1993). Species identification and chemical analysis of psychoactive fungi in the Hawaiian islands. Journal of Ethnopharmacology.

Gartz (1994). Extraction and analysis of indole derivatives from fungal biomass. Journal of Basic Microbiology.

Gartz, Allen & Merlin (1994). Ethnomycology, biochemistry, and cultivation of Psilocybe samuiensis Guzmán, Bandala and Allen, a new psychoactive fungus from Koh Samui, Thailand. Journal of Ethnopharmacology.

Marcano et al. (1994). Occurrence of psilocybin and psilocin in Psilocybe pseudobullacea (Petch) Pegler from the Venezuelan Andes. Journal of Ethnopharmacology.

Bergman & Karlsson (1995). [A caution for psilocybine in wild mushrooms. A young addict acquired acute delirium].

Hanes (1996). Serotonin, psilocybin, and body dysmorphic disorder: a case report. Journal of Clinical Psychopharmacology.

Spitzer et al. (1996). Increased activation of indirect semantic associations under psilocybin. Biological Psychiatry.

Babakhanian et al. (1997). [The toxicological aspects of poisonings by psilocybine-containing mushrooms]. Sudebno-Meditsinskaia Ekspertiza.

Franz et al. (1996). Magic mushrooms: hope for a 'cheap high' resulting in end-stage renal failure. Nephrology, Dialysis, Transplantation.

Hasler et al. (1997). Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharmaceutica Acta Helvetiae.

Holm et al. (1997). [Hallucinogenic mushrooms in Denmark]. Ugeskrift for Laeger.

Moreno & Delgado (1997). Hallucinogen-induced relief of obsessions and compulsions. The American Journal of Psychiatry.

Pedersen-Bjergaard (1997). Determination of psilocybin in Psilocybe semilanceata by capillary zone electrophoresis. Journal of Chromatography.

Vollenweider (1997). Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology.

Babakhanian et al. (1998). [The forensic chemical study of psilocybine-containing fungi]. Sudebno-Meditsinskaia Ekspertiza.

Beck et al. (1998). Presence of phenylethylamine in hallucinogenic Psilocybe mushroom: possible role in adverse reactions. Journal of Analytical Toxicology.

Bogusz et al. (1998). Honey with Psilocybe mushrooms: a revival of a very old preparation on the drug market? International Journal of Legal Medicine.

Borowiak et al. (1998). Psilocybin mushroom (Psilocybe semilanceata) intoxication with myocardial infarction. Journal of Toxicology.

Doblin (1998). Dr. Leary's Concord Prison Experiment: A 34-year follow-up study. Journal of Psychoactive Drugs.

Gouzoulis-Mayfrank et al. (1998). Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Behavioural Pharmacology.

Gouzoulis-Mayfrank et al. (1998). Methodological issues of human experimental research with hallucinogens. Pharmacopsychiatry.

Metzner (1998). Reflections on the Concord Prison project and the follow-up study. Journal of Psychoactive Drugs.

Pedersen-Bjergaard et al. (1998). Strategies for the capillary electrophoretic separation of indole alkaloids in Psilocybe semilanceata. Electrophoresis.

Vollenweider et al. (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport.

Babakhanian et al. (1999). [The morphofunctional changes in the internal organs in the modelling of poisonings by psilocybine-containing mushrooms]. Sudebno-Meditsinskaia Ekspertiza.

Gouzoulis-Mayfrank (1999). Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology.

Gouzoulis-Mayfrank (1999). Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology.

Keller et al. (1999). Analysis of psilocybin and psilocin in Psilocybe subcubensis Guzmán by ion mobility spectrometry and gas chromatography-mass spectrometry. Forensic Science International.

Vollenweider et al. (1999). 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man—A PET study with [¹¹C]raclopride. Neuropsychopharmacology.

Westberg & Karlson-Stiber (1999). [Hallucinogenic mushrooms popular again--sale via Internet]. Lakartidningen.

Lee, Cole & Linacre (2000). Identification of members of the genera Panaeolus and Psilocybe by a DNA test. A preliminary test for hallucinogenic fungi. Forensic Science International.

Sticht & Käferstein (2000). Detection of psilocin in body fluids. Forensic Science International.

Grieshaber, Moore & Levine (2001). The detection of psilocin in human urine. Journal of Forensic Sciences.

Moldavan et al. (2001). The effect of Psilocybe cubensis extract on hippocampal neurons in vitro. Fiziolohichnyi Zhurnal.

Albers et al. (2002). Synthesis of a psilocin hapten and a protein-hapten conjugate. The Journal of Pharmacy and Pharmacology.

Gouzoulis-Mayfrank et al. (2002). Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans. Neuropsychobiology.

Hasler et al. (2002). Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man. The Journal of Pharmaceutical and Biomedical Analysis.

Passie et al. (2002). The pharmacology of psilocybin. Addiction Biology.

Kamata et al. (2003). Optimized glucuronide hydrolysis for the detection of psilocin in human urine samples. Journal of Chromatography.

Maruyama et al. (2003). [Discrimination of psychoactive fungi (commonly called "magic mushrooms") based on the DNA sequence of the internal transcribed spacer region]. Shokuhin Eiseigaku Zasshi.

Shirota, Hakamata & Goda (2003). Concise large-scale synthesis of psilocin and psilocybin, principal hallucinogenic constituents of "magic mushroom". Journal of Natural Products.

Stríbrný, Borovicka & Sokol (2003). [Levels of psilocybin and psilocin in various types of mushrooms]. Soudni Lekarstvi.

Tsujikawa et al. (2003). Morphological and chemical analysis of magic mushrooms in Japan. Forensic Science International.

Umbricht et al. (2003). Effects of the 5-HT 2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: Implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology.

Albers et al. (2004). Development of a psilocin immunoassay for serum and blood samples. International Journal of Legal Medicine.

Beuhler, Lee & Gerkin (2004). The Meixner test in the detection of alpha-amanitin and false-positive reactions caused by psilocin and 5-substituted tryptamines. Annals of Emergency Medicine.

Carter et al. (2004). Psilocybin impairs high-level but not low-level motion perception. NeuroReport.

Hasler et al. (2004). Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study. Psychopharmacology.

Nugent & Saville (2004). Forensic analysis of hallucinogenic fungi: a DNA-based approach. Forensic Science International.

Anastos et al. (2005). Determination of psilocin and psilocybin using flow injection analysis with acidic potassium permanganate and tris(2,2'-bipyridyl)ruthenium(II) chemiluminescence detection respectively. Talanta.

Bickel et al. (2005). Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after 'magic mushroom' abuse. European Journal of Emergency Medicine.

Carter et al. (2005). Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-ht 2a and 5-ht 1a agonist psilocybin. Neuropsychopharmacology.

Carter et al. (2005). Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. Journal of Cognitive Neuroscience.

Espiard et al. (2005). Hallucinogen persisting perception disorder after psilocybin consumption: A case study. European Psychiatry.

Kamata et al. (2005). Liquid chromatography-mass spectrometric and liquid chromatography-tandem mass spectrometric determination of hallucinogenic indoles psilocin and psilocybin in "magic mushroom" samples. Journal of Forensic Sciences.

Reingardiene et al. (2005). [Hallucinogenic mushrooms]. Medicina.

Saito et al. (2005). Determination of psilocybin in hallucinogenic mushrooms by reversed-phase liquid chromatography with fluorescence detection. Talanta.

Sard et al. (2005). SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorganic & Medicinal Chemistry Letters.

Satora, Goszcz & Ciszowski (2005). Poisonings resulting from the ingestion of magic mushrooms in Kraków. Przeglad Lekarski.

Anastos et al. (2006). Investigation into the temporal stability of aqueous standard solutions of psilocin and psilocybin using high performance liquid chromatography. Science & Justice.

Anastos et al. (2006). The determination of psilocin and psilocybin in hallucinogenic mushrooms by HPLC utilizing a dual reagent acidic potassium permanganate and tris(2,2'-bipyridyl)ruthenium(II) chemiluminescence detection system. Journal of Forensic Sciences.

Griffiths et al. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology.

Jensen, Gartz & Laatsch (2006). Aeruginascin, a trimethylammonium analogue of psilocybin from the hallucinogenic mushroom Inocybe aeruginascens. Planta Medica.

Maruyama et al. (2006). Phylogenetic relationship of psychoactive fungi based on rRNA gene for a large subunit and their identification using the TaqMan assay (II). Forensic Science International.

Moreno et al. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry.

Sempere et al. (2006). [Chronic cluster headache: Response to psilocybin]. Revista de Neurologia.

Sewell, Halpern & Pope (2006). Response of cluster headache to psilocybin and LSD. Neurology.

Attema-de Jonge et al. (2007). [Automutilation after consumption of hallucinogenic mushrooms]. Nederlands tijdschrift voor geneeskunde.

Carter et al. (2007). Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology.

Vollenweider et al. (2007). The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology.

Winter et al. (2007). Psilocybin-induced stimulus control in the rat. Pharmacology, Biochemistry and Behavior.

Wittmann et al. (2007). Effects of psilocybin on time perception and temporal control of behaviour in humans. Journal of Psychopharmacology.

Griffiths et al. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology.

McClintock, Watts & Melanson (2008). Unrecognized magic mushroom abuse in a 28-year-old man. The American Journal of Emergency Medicine.

Richards (2008). The phenomenology and potential religious import of states of consciousness facilitated by psilocybin. Archive for the Psychology of Religions.

Wackermann et al. (2008). Effects of varied doses of psilocybin on time interval reproduction in human subjects. Neuroscience Letters.

Barbee et al. (2009). Analysis of mushroom exposures in Texas requiring hospitalization, 2005-2006. Journal of Medical Toxicology.

Kovacic (2009). Unifying electron transfer mechanism for psilocybin and psilocin. Medical Hypotheses.

Lott, Marlowe & Forman (2009). Availability of websites offering to sell psilocybin spores and psilocybin. Journal of Psychoactive Drugs.

Matsushima et al. (2009). Effects of Psilocybe argentipes on marble-burying behavior in mice. Bioscience, Biotechnology, and Biochemistry.

Riley, Thompson & Griffin (2010). Turn on, tune in, but don't drop out: The impact of neo-liberalism on magic mushroom users' (in)ability to imagine collectivist social worlds. The International Journal on Drug Policy.

Koçak. De Cotiis & Hoffman (2010). Comparative study of ATR and transflection IR spectroscopic techniques for the analysis of hallucinogenic mushrooms. Forensic Science International.

Laussmann & Meier-Giebing (2010). Forensic analysis of hallucinogenic mushrooms and khat (Catha edulis Forsk) using cation-exchange liquid chromatography. Forensic Science International.

Manevski et al. (2010). Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases. Drug Metabolism and Disposition.

Wark & Galliher (2010). Timothy Leary, Richard Alpert (Ram Dass) and the changing definition of psilocybin. International Journal of Drug Policy.

Carhart-Harris et al. (2011). The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: A preliminary investigation of tolerability. Journal of Psychopharmacology.

Griffiths et al. (2011). Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology.

Grob et al. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry.

MacLean et al. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology.

Kometer et al. (2011). The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biological Psychiatry.

Shoda et al. (2011). Enzyme-assisted synthesis of the glucuronide conjugate of psilocin, an hallucinogenic component of magic mushrooms. Drug Testing and Analysis.

Studerus et al. (2011). Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies. Journal of Psychopharmacology.

van Amsterdam et al. (2011). Harm potential of magic mushroom use: a review.

Carhart-Harris et al. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. PNAS.

Carhart-Harris et al. (2012). Implications for psychedelic-assisted psychotherapy: Functional magnetic resonance imaging study with psilocybin. The British Journal of Psychiatry.

Kometer et al. (2012). Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biological Psychiatry.

Johnson, Sewell & Griffiths (2012). Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug and Alcohol Dependence.

Lim, Wasywich & Ruygrok (2012). A fatal case of 'magic mushroom' ingestion in a heart transplant recipient. Internal Medicine Journal.

Lyvers & Meester (2012). Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner. Journal of Psychoactive Drugs.

MacLean et al. (2012). Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. Journal for the Scientific Study of Religion.

Martin et al. (2012). A validated method for quantitation of psilocin in plasma by LC-MS/MS and study of stability. International Journal of Legal Medicine.

Quednow et al. (2012). Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology.

Roiser & Rees (2012). Neuroimaging: A Scanner, Colourfully. Current Biology.

Studerus et al. (2012). Prediction of psilocybin response in healthy volunteers. PLoS ONE. 

Bogenschutz (2013). Studying the effects of classic hallucinogens in the treatment of alcoholism: rationale, methodology, and current research with psilocybin. Current Drug Abuse Reviews.

Carhart-Harris (2013). Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophrenia Bulletin.

Catlow et al. (2013). Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Experimental Brain Research.

Cummins & Lyke (2013). Peak experiences of psilocybin users and non-users. Journal of Psychoactive Drugs.

Hallock et al. (2013). A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students. Drug and Alcohol Dependence.

Jastrzebski & Bala (2013). [The impact of psilocybin on visual perception and spatial orientation--neuropsychological approach]. Psychiatria Polska.

Kometer et al. (2013). Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. The Journal of Neuroscience.

Kosentka et al. (2013). Evolution of the toxins muscarine and psilocybin in a family of mushroom-forming fungi. PLOS One.

Krebs & Johansen (2013). Psychedelics and Mental Health: A Population Study. PLoS ONE.

Martin et al. (2013). Determination of psilocin, bufotenine, LSD and its metabolites in serum, plasma and urine by SPE-LC-MS/MS. International Journal of Legal Medicine.

Müller et al. (2013). [Suicide under the influence of "magic mushrooms"]. Archiv fur Kriminologie.

Muthukumaraswamy et al. (2013). Broadband cortical desynchronization underlies the human psychedelic state. The Journal of Neuroscience.

Pellegrini et al. (2013). Magic truffles or Philosopher's stones: a legal way to sell psilocybin? Drug Testing and Analysis.

Schmidt et al. (2013). The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacology.

Stebelska (2013). Fungal hallucinogens psilocin, ibotenic acid, and muscimol: analytical methods and biologic activities. Therapeutic Drug Monitoring.

Young (2013). Single treatments that have lasting effects: Some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin. Journal of Psychiatry & Neuroscience.

Bernasconi et al. (2014). Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin. Cerebral Cortex.

Bradstreet et al. (2014). Characterization of challenging experiences (i.e., bad trips) after ingesting psilocybin. Drug and Alcohol Dependence.

Carhart-Harris et al. (2014). The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Frontiers in Human Neuroscience.

Dos Santos (2014). Potential therapeutic effects of psilocybin/psilocin are minimized while possible adverse reactions are overrated.

Garcia-Romeu, Griffiths & Johnson (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews.

Hendricks (2014). Back to the future: A return to psychedelic treatment models for addiction. Journal of Psychopharmacology.

Hendricks et al. (2014). Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. Journal of Psychopharmacology.

Johnson et al. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology.

Martin et al. (2014). Synthesis, hydrolysis and stability of psilocin glucuronide. Forensic Science International.

Nichols (2014). The Heffter Research Institute: Past and hopeful future. Journal of Psychoactive Drugs.

Rambousek et al. (2014). The effect of psilocin on memory acquisition, retrieval, and consolidation in the rat. Frontiers in Behavioral Neuroscience.

Roseman et al. (2014). The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Frontiers in Human Neuroscience.

Sevanick (2014). Psilocybin-Assisted Psychotherapy in the Treatment of Cancer-Related Psychosocial Distress/Anxiety. Psycho – Oncology.

Tagliazucchi et al. (2014). Enhanced repertoire of brain dynamical states during the psychedelic experience. Human Brain Mapping.

Turton, Nutt & Carhart-Harris (2014). A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment. Current Drug Abuse Reviews.

Tylš, Páleníček & Horáček (2014). Psilocybin—Summary of knowledge and new perspectives. European Neuropsychopharmacology.

Wilcox (2014). Psilocybin and obsessive compulsive disorder. Journal of Psychoactive Drugs. 

Barrett, Johnson & Griffiths (2015). Validation of the revised mystical experiences questionnaire in experimental sessions with psilocybin. Drug and Alcohol Dependence.

Bogenschutz et al. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology.

Borovička et al. (2015). Phylogenetic and chemical studies in the potential psychotropic species complex of Psilocybe atrobrunnea with taxonomic and nomenclatural notes. Persoonia.

Carbonaro et al. (2015). Comparative phenomenology of psilocybin experiences in research and non-research settings. Drug and Alcohol Dependence.

Dydak et al. (2015). [Psilocybin - public available psychodysleptic]. Postepy Higieny I Medycyny Doswiadczalnej.

Gallimore (2015). Restructuring consciousness—The psychedelic state in light of integrated information theory. Frontiers in Human Neuroscience.

Garcia-Romeu, Griffiths & Johnson (2015). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews.

Garcia-Romeu et al. (2015). Long-term follow-up of psilocybin-facilitated smoking cessation: Abstinence outcomes and qualitative analysis of participant accounts. Drug and Alcohol Dependence.

Gartz & Wiedemann (2015). Discovery of a new caerulescent Psilocybe mushroom in Germany: Psilocybe germanica sp.nov. Drug Testing and Analysis.

Geyer (2015). Lysergic Acid Diethylamide and Psilocybin Revisited. Biological Psychiatry.

Hendricks, Johnson & Griffiths (2015). Psilocybin, psychological distress, and suicidality. Journal of Psychopharmacology.

Kometer et al. (2015). Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations. Psychopharmacology

Kraehenmann et al. (2015). Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biological Psychiatry.

Kraehenmann et al. (2015). The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. NeuroImage Clinical.

Lebedev et al. (2015). Finding the self by losing the self: Neural correlates of ego‐dissolution under psilocybin. Human Brain Mapping.

Martin et al. (2015). Analysis of psilocin, bufotenine and LSD in hair. Journal of Analytical Toxicology.

Sakashita et al. (2015). Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats. Biological & Pharmaceutical Bulletin.

Schindler et al. (2015). Indoleamine hallucinogens in cluster headache: results of the clusterbusters medication use survey. Journal of Psychoactive Drugs.

Spain et al. (2015). Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain. Neuropharmacology.

Tittarelli et al. (2015). Recreational use, analysis and toxicity of tryptamines. Current Neuropharmacology.

Zhuk et al. (2015). Research on acute toxicity and the behavioral effects of methanolic extract from psilocybin mushrooms and psilocin in mice.

Barrett et al. (2016). The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms. Journal of Psychopharmacology.

Breckenridge & Grobbee (2016). Psilocybin: promising results in double-blind trials require confirmation by real-world evidence. Journal of Psychopharmacology.

Carbonaro et al. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology.

Carhart-Harris (2016). "Question-based Drug Development for psilocybin": Authors' reply. The Lancet Psychiatry.

Carhart-Harris (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry.

Cowen (2016). Altered states: Psilocybin for treatment-resistant depression. The Lancet Psychiatry.

Davenport (2016). Psychedelic and nonpsychedelic LSD and psilocybin for cluster headache. CMAJ.

Dijkstra, Jacobs & Cohen (2016). Question-based drug development for psilocybin. The Lancet Psychiatry.

Dos Santos et al. (2016). Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Therapeutic Advances in Psychopharmacology.

Gambaro et al. (2016). DNA-based taxonomic identification of basidiospores in hallucinogenic mushrooms cultivated in "grow-kits" seized by the police: LC-UV quali-quantitative determination of psilocybin and psilocin. Journal of Pharmaceutical and Biomedical Analysis.

Goodwin (2016). Psilocybin: Psychotherapy or drug? Journal of Psychopharmacology.

Griffiths et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology.

Hawkes (2016). Sixty seconds on . . . psilocybin. BMJ.

Hendrie & Pickles (2016). Psilocybin: panacea or placebo? The Lancet Psychiatry.

Kelmendi et al. (2016). The role of psychedelics in palliative care reconsidered: A case for psilocybin. Journal of Psychopharmacology.

McCorvy, Olsen & Roth (2016). Psilocybin for depression and anxiety associated with life-threatening illnesses. Journal of Psychopharmacology.

Mithoefer, Grob & Brewerton (2016). Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. The Lancet Psychiatry.

Nutt (2016). Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future. Journal of Psychopharmacology.

Patra (2016). Return of the psychedelics: Psilocybin for treatment resistant depression. Asian Journal of Psychiatry.

Pokorny et al. (2016). Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. The Lancet Psychiatry.

Preller et al. (2016). Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. PNAS.

Ross et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology.

Shebloski & Broadway (2016). Commentary: Effects of psilocybin on time perception and temporal control of behavior in humans. Frontiers in Psychology.

Shelton & Hendricks (2016). Psilocybin and palliative end-of-life care. Journal of Psychopharmacology.

Spiegel (2016). Psilocybin-assisted psychotherapy for dying cancer patients - aiding the final trip. Journal of Psychopharmacology.

Summergrad (2016). Psilocybin in end of life care: Implications for further research. Journal of Psychopharmacology.

Suzuki (2016). [Three cases of acute serotonin syndrome due to psilocybin mushroom poisoning]. Chudoku Kenkyu.

Tylš et al. (2016). Sex differences and serotonergic mechanisms in the behavioural effects of psilocin. Behavioural Pharmacology.

Barrett, Johnson & Griffiths (2017). Neuroticism is associated with challenging experiences with psilocybin mushrooms. Personality and Individual Differences.

Belser et al. (2017). Patient experiences of psilocybin-assisted psychotherapy: An interpretative phenomenological analysis. Journal of Humanistic Psychology.

Bogenschutz (2017). It’s time to take psilocybin seriously as a possible treatment for substance use disorders. The American Journal of Drug and Alcohol Abuse.

Bogenschutz & Forcehimes (2017). Development of a psychotherapeutic model for psilocybin-assisted treatment of alcoholism. Journal of Humanistic Psychology.

Brown et al. (2017). Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clinical Pharmacokinetics.

Carhart-Harris et al. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports.

de Veen et al. (2017). Psilocybin for treating substance use disorders? Expert Review of Neurotherapeutics.

Dinis-Oliveira (2017). Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metabolism Reviews.

Fricke, Blei & Hoffmeister (2017). Enzymatic synthesis of psilocybin. Angewandte Chemie International Edition.

Geller (2017). Can Psilocybin Treat Severe Depression? NEJM Journal Watch. Psychiatry.

Johnson & Griffiths (2017). Potential therapeutic effects of psilocybin. Neurotherapeutics.

Johnson et al. (2017). An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. Journal of Psychopharmacology.

Johnson, Garcia-Romeu & Griffiths (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse.

Johnson et al. (2017). "Long-term follow-up of psilocybin-facilitated smoking cessation": Corrigendum. The American Journal of Drug and Alcohol Abuse.

Lewis et al. (2017). Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. NeuroImage.

Mahapatra & Gupta (2017). Role of psilocybin in the treatment of depression. Therapeutic Advances in Psychopharmacology.

Pokorny et al. (2017). Effect of psilocybin on empathy and moral decision-making. International Journal of Neuropsychopharmacology.

Roseman et al. (2017). Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology.

Schartner et al. (2017). Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. Scientific Reports.

Sellers (2017). Psilocybin: Good Trip or Bad Trip. Clinical Pharmacology and Therapeutics.

Strauss (2017). Psilocybin-assisted therapy for anxiety and depression: implications for euthanasia. The Medical Journal of Australia.

Swift et al. (2017). Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress. The Journal of Humanistic Psychology.

Thomas, Malcolm & Lastra (2017). Psilocybin-assisted therapy: A review of a novel treatment for psychiatric disorders. Journal of Psychoactive Drugs.

Barnby & Mehta. (2018). Psilocybin and Mental Health-Don't Lose Control. Frontiers in Psychiatry.

Blei et al. (2018). Biocatalytic production of psilocybin and derivatives in tryptophan synthase-enhanced reactions. Chemistry.

Bogenschutz et al. (2018). Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder. Frontiers in Pharmacology.

Bravermanová et al. (2018). Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing—Study on P300 and mismatch negativity in healthy volunteers. Psychopharmacology.

Carbonaro et al. (2018). Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: Similarities and differences in subjective experiences. Psychopharmacology.

Carhart-Harris et al. (2018). Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology.

Carrillo et al. (2018). Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. Journal of Affective Disorders.

Daniel & Haberman (2018). Clinical potential of psilocybin as a treatment for mental health conditions. The Mental Health Clinician.

Fricke et al. (2018). Production options for psilocybin - the making of the magic. Chemistry.

Erritzoe et al. (2018). Effects of psilocybin therapy on personality structure. Acta Psychiatrica Scandinavica.

Gabay et al. (2018). Psilocybin and MDMA reduce costly punishment in the Ultimatum Game. Science Reports.

Geiger, Wurst & Daniels. (2018). DARK Classics in Chemical Neuroscience: Psilocybin. ACS Chemical Neuroscience.

Griffiths et al. (2018). Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology.

Grimm et al. (2018). Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination. European Neuropsychopharmacology.

Hendricks et al. (2018). The relationships of classic psychedelic use with criminal behavior in the United States adult population. Journal of Psychopharmacology.

Johnson et al. (2018). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology.

Lyons & Carhart-Harris (2018). Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. Journal of Psychopharmacology.

Individual experiences in four cancer patients following psilocybin-assisted psychotherapy. Frontiers in Pharmacology.

Nicholas et al. (2018). High dose psilocybin is associated with positive subjective effects in healthy volunteers. Journal of Psychopharmacology.

Noorani et al. (2018). Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. Journal of Psychopharmacology.

Ramachandran et al. (2018). Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF). Neurocase.

Roseman, Nutt & Carhart-Harris (2018). Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Frontiers in Pharmacology.

Schenberg (2018) Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. Frontiers in Pharmacology.

Stroud et al. (2018). Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychopharmacology.

Whelan & Johnson (2018). Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role? Pain Management.